drugset
Drugs / XmAb942
last change May 2026 re-read 3 minutes ago

XmAb942

Developed for
ulcerative colitis

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1/2 NCT06619990 Comparator Oct 2024 → Apr 2028 expected ulcerative colitis Xencor, Inc. Recruiting No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2026-05-04 Xencor, Inc. Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW xencor.com ↗
2025-04-29 Xencor, Inc. Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease xencor.com ↗
2024-10-10 Xencor, Inc. Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases xencor.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as XmAb942 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06619990 ↗
Route Intravenous “via SC (3 cohorts) or IV (3 cohorts) administration” NCT06619990 ↗
Route Subcutaneous “via SC (3 cohorts) or IV (3 cohorts) administration” NCT06619990 ↗